



Deposited via The University of York.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/211412/>

Version: Published Version

---

**Article:**

Taylor, Jo, Mitchell, Alex, Hall, Ruth et al. (2024) Interventions to suppress puberty in adolescents experiencing gender dysphoria or incongruence: a systematic review. Archives of Disease in Childhood. ISSN: 1468-2044

<https://doi.org/10.1136/archdischild-2023-326669>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



OPEN ACCESS

# Interventions to suppress puberty in adolescents experiencing gender dysphoria or incongruence: a systematic review

Jo Taylor , Alex Mitchell, Ruth Hall, Claire Heathcote, Trilby Langton, Lorna Fraser, Catherine Elizabeth Hewitt

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/archdischild-2023-326669>).

Department of Health Sciences, University of York, York, UK

## Correspondence to

Dr Jo Taylor, Health Sciences, University of York, York, North Yorkshire, UK; [dohs-gender-research@york.ac.uk](mailto:dohs-gender-research@york.ac.uk)

Received 25 November 2023  
Accepted 10 February 2024



- <https://doi.org/10.1136/archdischild-2023-326112>
- <https://doi.org/10.1136/archdischild-2023-326347>
- <https://doi.org/10.1136/archdischild-2023-326348>
- <https://doi.org/10.1136/archdischild-2023-326500>
- <https://doi.org/10.1136/archdischild-2023-326499>
- <https://doi.org/10.1136/archdischild-2023-326760>
- <https://doi.org/10.1136/archdischild-2023-326670>
- <https://doi.org/10.1136/archdischild-2023-326681>



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Taylor J, Mitchell A, Hall R, et al. *Arch Dis Child* Epub ahead of print: [please include Day Month Year]. doi:10.1136/archdischild-2023-326669

## ABSTRACT

**Background** Treatment to suppress or lessen effects of puberty are outlined in clinical guidelines for adolescents experiencing gender dysphoria/incongruence. Robust evidence concerning risks and benefits is lacking and there is a need to aggregate evidence as new studies are published.

**Aim** To identify and synthesise studies assessing the outcomes of puberty suppression in adolescents experiencing gender dysphoria/incongruence.

**Methods** A systematic review and narrative synthesis. Database searches (Medline, Embase, CINAHL, PsycINFO, Web of Science) were performed in April 2022, with results assessed independently by two reviewers. An adapted version of the Newcastle-Ottawa Scale for cohort studies was used to appraise study quality. Only moderate-quality and high-quality studies were synthesised. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines were used.

**Results** 11 cohort, 8 cross-sectional and 31 pre-post studies were included (n=50). One cross-sectional study was high quality, 25 studies were moderate quality (including 5 cohort studies) and 24 were low quality. Synthesis of moderate-quality and high-quality studies showed consistent evidence demonstrating efficacy for suppressing puberty. Height increased in multiple studies, although not in line with expected growth. Multiple studies reported reductions in bone density during treatment. Limited and/or inconsistent evidence was found in relation to gender dysphoria, psychological and psychosocial health, body satisfaction, cardiometabolic risk, cognitive development and fertility.

**Conclusions** There is a lack of high-quality research assessing puberty suppression in adolescents experiencing gender dysphoria/incongruence. No conclusions can be drawn about the impact on gender dysphoria, mental and psychosocial health or cognitive development. Bone health and height may be compromised during treatment. More recent studies published since April 2022 until January 2024 also support the conclusions of this review.

**PROSPERO registration number** CRD42021289659.

## INTRODUCTION

Over the last 10-15 years, increasing numbers of children and adolescents experiencing gender dysphoria/incongruence are being referred to specialist paediatric gender services.<sup>1,2</sup>

## WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Increasing numbers of children and adolescents experiencing gender dysphoria/incongruence are being referred to specialist gender services.
- ⇒ National and international guidelines have changed over time and outline that medications to suppress puberty can be considered for adolescents experiencing gender dysphoria/incongruence.
- ⇒ Several systematic reviews report a limited evidence base for these treatments, and uncertainty about the benefits, risks and long-term effects.

## WHAT THIS STUDY ADDS

- ⇒ No high-quality studies were identified that used an appropriate study design to assess the outcomes of puberty suppression in adolescents experiencing gender dysphoria/incongruence.
- ⇒ There is insufficient and/or inconsistent evidence about the effects of puberty suppression on gender-related outcomes, mental and psychosocial health, cognitive development, cardiometabolic risk, and fertility.
- ⇒ There is consistent moderate-quality evidence, although from mainly pre-post studies, that bone density and height may be compromised during treatment.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, POLICY OR PRACTICE

- ⇒ There is a lack of high-quality evidence to support the use of puberty suppression in adolescents experiencing gender dysphoria/incongruence, and large well-designed research is needed.

Gender dysphoria/incongruence in childhood is associated with high rates of co-occurring mental health and psychosocial difficulties, which can affect health and well-being.<sup>3</sup> Clinical guidelines recommend psychosocial care to alleviate gender-related distress and any co-occurring difficulties. For pubertal adolescents, medications to suppress or lessen effects of puberty are also outlined. Gonadotropin-releasing hormone analogues (GnRH-a) are used as first-line treatment, although other drugs with anti-androgenic properties including progestins and spironolactone are used in this population.<sup>4,5</sup> The effects differ depending on

whether they are initiated in early puberty or mid-puberty, as well as the type of intervention used, with GnRH-a suppressing puberty when started early or suspending further progression when initiated in mid-puberty, and anti-androgens instead blocking specific downstream effects of sex hormones.<sup>4</sup>

Rationales for puberty suppression in the Dutch treatment protocol, which has informed practice internationally, were to alleviate worsening gender dysphoria, allow time for gender exploration, and pause development of secondary sex characteristics to make passing in the desired gender role easier.<sup>6</sup> Practice guidelines propose other indications for puberty suppression, including allowing time and/or capacity for decision-making about masculinising or feminising hormone interventions, and improving quality of life.<sup>4,7,8</sup>

Criteria in early treatment protocols for puberty suppression specified adolescents be at least age 12 years, at Tanner stage 2 in puberty, experienced gender dysphoria in childhood which persisted and intensified during puberty and met criteria for diagnosis of gender dysphoria.<sup>6</sup> It was also expected that any psychosocial difficulties that could interfere with treatment were managed.<sup>6</sup> The World Professional Association for Transgender Health standards of care<sup>4</sup> and other practice guidelines<sup>5,8,9</sup> have broadened these criteria, for example, removing minimum age. However, other recent guidelines have taken a more cautious approach and restricted inclusion criteria in response to uncertainties in the evidence base.<sup>7,10</sup>

Systematic reviews have consistently found mainly low-quality evidence, limited data on key outcomes or long-term follow-up.<sup>11–16</sup> These reviews report that while puberty suppression may offer some benefit, there are concerns about the impact on bone health, and uncertainty regarding cognitive development, psychosocial outcomes and cardiometabolic health. They conclude there is insufficient evidence to support clinical recommendations.

The proliferation of research in this area and lack of evidence to support practice means there is an ongoing need to aggregate evidence. This systematic review aims to synthesise evidence published to April 2022 that reports outcomes of puberty suppression in adolescents experiencing gender dysphoria/incongruence.

## METHODS

The review forms part of a linked series examining the epidemiology, care pathways, outcomes and experiences for children and adolescents experiencing gender dysphoria/incongruence and is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<sup>17</sup> The protocol was registered on PROSPERO (CRD42021289659).<sup>18</sup>

### Search strategy

A single search strategy was used to identify studies comprising two combined concepts: ‘children’, which included all terms for children and adolescents and ‘gender dysphoria’, which included associated terms such as gender-related distress and gender incongruence, and gender identity terms including transgender, gender diverse and non-binary.

MEDLINE (online supplemental table S1), EMBASE and PsycINFO through OVID, CINAHL Complete through EBSCO, and Web of Science (Social Science Citation Index) were searched (13–23 May 2021 and updated on 27 April 2022).

Reference lists of included studies and relevant systematic reviews were assessed for inclusion.<sup>11–16,19,20</sup>

**Table 1** Inclusion and exclusion criteria

Population	Children and/or adolescents aged 0–18 years experiencing gender dysphoria, gender incongruence or referral to a gender identity service. Studies of adults or a mixed population of adolescents and adults where treatment was initiated in childhood (<18 years).
Intervention	GnRH-a, progestins and other anti-androgens used to suppress puberty or part of puberty (eg, menstrual suppression).
Comparator	Any or none.
Outcomes	Expected or desired physiological effects, side effects, gender dysphoria or other gender-related outcomes, mental/psychological health, physical health, psychosocial outcomes, cognitive outcomes, fertility.
Study design	Clinical trials, cohort studies, case-control studies, cross-sectional studies, pre-post single-group design studies or service evaluations that provided treatment outcome data. Case studies and case series were excluded.
Publication	Studies published in the English language in a peer-reviewed journal. Conference abstracts were excluded.
GnRH-a, gonadotropin-releasing hormone analogues.	

### Inclusion criteria

The review included published research that reported outcomes of interventions used to suppress puberty for children and/or adolescents experiencing gender dysphoria/incongruence (table 1).

### Selection process

The results of database and other searches were uploaded to Covidence<sup>21</sup> and screened independently by two reviewers. Full texts of potentially relevant articles were retrieved and reviewed against inclusion criteria by two reviewers independently. Disagreements were resolved through discussion and inclusion of a third reviewer.

### Data extraction

Data on study characteristics, methods and reported outcomes were extracted into prepiloted data extraction templates by one reviewer and second-checked by another.

### Study quality

Critical appraisal was undertaken by two reviewers independently, with consensus reached through discussion and involvement of a third reviewer where necessary.

Quality was assessed using a modified version (online supplemental file 1) of the Newcastle-Ottawa Scale for cohort studies, a validated scale of eight items covering three domains: selection, comparability and outcome.<sup>22</sup> Scale modification included not scoring certain question(s) for cross-sectional and single-group designs, or particular outcomes; specification of key confounders to assess comparability of cohorts; guidance regarding sufficiency of follow-up and use of numerical scores for items and overall (maximum score 9 for cohorts, 8 for pre-post and cross-sectional studies with comparator). Total scores were calculated as percentages to account for different total scores ( $\leq 50\%$  low quality,  $>50\%$ – $75\%$  moderate quality,  $>75\%$  high quality).

### Synthesis

Narrative synthesis methods were used because of heterogeneity in study design, intervention, comparator, outcome and measurement. Due to high risk of bias in low-quality studies, these were excluded from the synthesis.




Figure 1 Study flow diagram.

When synthesising results by outcome domains, care was taken to differentiate between different study designs, comparators and interventions. Where possible, potential differences in effects by birth-registered sex, treatment duration or treatment in early puberty versus late puberty were examined.

## RESULTS

The database search yielded 28 147 records, 3181 of which were identified as potentially relevant for the linked systematic reviews and full texts reviewed. From these, 50 studies met inclusion criteria for this review (figure 1).

### Study characteristics

Studies were published from 2006 to 2022 with the majority published in 2020–2022 (n=29). Studies were conducted in the Netherlands (n=17),<sup>23–39</sup> the US (n=15),<sup>40–54</sup> the UK (n=6),<sup>55–60</sup> Canada (n=4),<sup>61–64</sup> three in Belgium<sup>65–67</sup> and Israel<sup>68–70</sup> and one in Brazil<sup>71</sup> and Germany<sup>72</sup> (online supplemental table S2).

The 50 studies included 11 cohorts comparing adolescents experiencing gender dysphoria/incongruence receiving puberty suppression with a comparator,<sup>35 39–42 45 49 50 52 56 72</sup> 8 cross-sectional with a comparator<sup>23 33 37 47 51 53 60 71</sup> and 31 pre-post single group studies.<sup>24–32 34 36 38 43 44 46 48 54 55 57–59 61–70</sup> More than half of studies (n=29) used retrospective chart review.

All but 4 studies selected adolescents experiencing gender dysphoria/incongruence from specialist gender or endocrinology services: 43 from single services (in Belgium, Israel, the Netherlands and the UK these were large regional or national services) and 3 from multiple US services.<sup>48–50</sup> The other four included three US studies (national survey recruiting via community settings,<sup>53</sup> clinical and community settings,<sup>51</sup> US Military Healthcare Data Repository<sup>54</sup>) and a study from Brazil recruiting via Facebook.<sup>71</sup>

Overall, studies included 10 673 participants: 9404 were adolescents experiencing gender dysphoria/incongruence (4702 received puberty suppression, 4702 did not) and 1269

other comparators. Comparator groups included adolescents or adults experiencing gender dysphoria/incongruence who had not received puberty suppression,<sup>35 39 40 42 51–53 60 71 72</sup> untreated adolescents not experiencing gender dysphoria/incongruence,<sup>36 47 50</sup> both of these comparators<sup>23 33 37 56</sup> or adolescents receiving treatment for a different medical reason.<sup>41 45 49</sup>

Most studies (n=39) assessed GnRH-a. In one, some participants received GnRH-a and some (birth-registered males) spironolactone.<sup>62</sup> In another, GnRH-a or progestins/anti-androgens were used but numbers taking each were not reported.<sup>40</sup> Among the other 11 studies, 5 assessed effects of progestins (cyproterone acetate,<sup>66 67</sup> lynestrenol,<sup>65 66</sup> medroxyprogesterone<sup>44</sup> and levonorgestrel-releasing intrauterine system<sup>41</sup>) as alternatives to GnRH-a,<sup>41 44 65–67</sup> 1 assessed bicalutamide<sup>46</sup> and 5 did not specify.<sup>43 52–54 71</sup>

Of the 50 studies, 29 reported outcomes for feminising or masculinising hormones as well as for puberty suppression, either by including a mixed sample of those receiving the two different interventions or by assessing those who progressed to hormones following puberty suppression.

The most frequently measured outcomes were puberty suppression (n=30) and physical health outcomes (n=27) (figure 2, online supplemental table S3). Gender-related outcomes and body image were measured in five and four studies, respectively. Psychological health was measured in 13 studies, psychosocial in 9 studies and cognitive/neurodevelopmental outcomes in 3 studies. Side effects were reported in six, bone health in nine, and one study measured fertility.

### Study quality

One cross-sectional study was rated high quality,<sup>37</sup> 25 moderate quality<sup>23 24 29–32 34–36 39 48–51 54–59 64 65 67–69</sup> and 24 low quality.<sup>25–28 33 38 40–47 52 53 60–63 66 70–72</sup> Of the 11 cohort studies, which were the only studies to include a comparator and assess outcomes over time, only 5 were rated moderate quality (figure 2, online supplemental table S4).<sup>35 39 49 50 56</sup>




Figure 2 Outcome categories by study quality and design.

In most studies, there were concerns about sample representativeness due to single site recruitment, inclusion of a selected group and/or poor reporting of the eligible population. In studies including a comparator, most did not report or control for key differences between groups and only four used matched controls.<sup>23 33 41 47</sup> Most studies presented results for birth-registered males and females separately or controlled for this. Few studies controlled for age or Tanner stage or co-interventions that could influence outcomes.

Overall, studies used appropriate methods to ascertain exposure and assess outcomes. Adequacy of follow-up was evident in 18 studies, with multiple studies not reporting treatment duration, including participants receiving treatment at baseline, and not aligning follow-up with treatment initiation. Missing data at follow-up/analysis or poor reporting of this affected many studies.

Four studies did not report separate outcome data for adolescents receiving puberty suppression or masculinising/feminising hormones.<sup>39 54 60 71</sup> Two of these were of moderate quality and not included in the synthesis,<sup>39 54</sup> one of which was the only study to assess fertility outcomes.<sup>39</sup> One moderate-quality study assessed amplitude of click-evoked otoacoustic emissions.<sup>23</sup> This was excluded from the synthesis on the basis of not being clinically relevant.

## Synthesis of outcomes

### Gender dysphoria and body satisfaction

Two pre-post studies measured gender dysphoria and body satisfaction (with primary and secondary sex or neutral body characteristics) and reported no change before and after receiving treatment<sup>24 55</sup> (table 2).

### Psychological health

One cross-sectional<sup>37</sup> and two pre-post studies<sup>24 55</sup> measured symptoms of depression (n=1), anxiety (n=1), anger (n=1), internalising and externalising symptoms (n=3), suicide and/or self-harm (n=2) and psychological functioning (n=2).

Three studies assessed internalising and externalising symptoms with one reporting improvements in both (pre-post<sup>24</sup>), one improvement in internalising but not externalising symptoms when compared with adolescents under assessment by a gender service (cross-sectional<sup>37</sup>) and one observed no change in either (pre-post).<sup>55</sup>

For other psychological outcomes, there was either a single study, or two studies showing inconsistent results, with studies reporting either a small to moderate significant improvement or no change (table 2).

### Psychosocial outcomes

One cohort<sup>56</sup> and two pre-post<sup>24 55</sup> studies measured psychosocial functioning, one pre-post study assessed quality of life<sup>55</sup> and one cross-sectional study measured peer-relations (table 2).<sup>37</sup>

For psychosocial functioning, both pre-post studies reported no clinically significant change at follow-up.<sup>24 55</sup> The cohort study compared adolescents who were not immediately eligible for puberty suppression and received psychological support only, and adolescents who additionally received GnRH-a after 6 months.<sup>56</sup> Improvements were seen in both groups after 6 months of psychological support. This improvement was maintained over time for those receiving psychological support only. For those receiving GnRH-a, further improvements were observed at 12 and 18 months. At 18 months, psychosocial functioning in this group was considerably higher than in those still waiting for puberty suppression, and similar to adolescents not

**Table 2** Gender-related, body image, psychological, psychosocial, and cognitive/neurodevelopmental outcomes

Study	Country	Study design	Study quality	Treated sample	Comparator	Intervention	Outcome (measure)	Follow-up specific to outcome	Summary of study results
<b>Gender-related outcomes</b>									
Carmichael <i>et al</i> <sup>55</sup>	UK	Pre-post	Moderate	44 (19 brf, 25 brm)	N/A	GnRH-a	Gender dysphoria (UGDS)	12 m, 24 m	No change over time.
de Vries <i>et al</i> <sup>24</sup>	The Netherlands	Pre-post	Moderate	70 (37 brf, 33 brm)	N/A	GnRH-a	Gender dysphoria (UGDS)	Before CSH start (range 0.4–5.1 y)	No change.
<b>Body image</b>									
Carmichael <i>et al</i> <sup>55</sup>	UK	Pre-post	Moderate	44 (19 brf, 25 brm)	N/A	GnRH-a	Satisfaction with primary or secondary sex, or neutral body characteristics (BIS)	12 m, 24 m, 36 m	No change over time.
de Vries <i>et al</i> <sup>24</sup>	The Netherlands	Pre-post	Moderate	70 (37 brf, 33 brm)	N/A	GnRH-a	Satisfaction with primary or secondary sex, or neutral body characteristics (BIS)	Before CSH start (range 0.4–5.1 y)	No change.
<b>Psychological health</b>									
<b>Depression</b>									
de Vries <i>et al</i> <sup>24</sup>	The Netherlands	Pre-post	Moderate	70 (37 brf, 33 brm)	N/A	GnRH-a	Depressive symptoms (BDI)	Before CSH start (range 0.4–5.1 y)	Reduction in depressive symptoms.
<b>Anxiety</b>									
de Vries <i>et al</i> <sup>24</sup>	The Netherlands	Pre-post	Moderate	70 (37 brf, 33 brm)	N/A	GnRH-a	Anxiety symptoms (STAI)	Before CSH start (range 0.4–5.1 y)	No change in anxiety symptoms.
<b>Internalising problems</b>									
van der Miesen <i>et al</i> <sup>37</sup>	The Netherlands	Cross-sectional	High	178 (110 brf, 68 brm)	272+651 no GD	GnRH-a	Internalising problems (YSR)	N/A	Fewer problems in those treated compared with not treated. Scores in treated brm similar to cisgender brm, and scores in treated brf lower than cisgender brf.
Carmichael <i>et al</i> <sup>55</sup>	UK	Pre-post	Moderate	44 (19 brf, 25 brm)	N/A	GnRH-a	Internalising problems (CBCL/YSR)	12 m, 24 m, 36 m	No change over time.
de Vries <i>et al</i> <sup>24</sup>	The Netherlands	Pre-post	Moderate	70 (37 brf, 33 brm)	N/A	GnRH-a	Internalising problems (CBCL/YSR)	Before CSH start (range 0.4–5.1 y)	Small decrease (improvement).
<b>Externalising problems</b>									
van der Miesen <i>et al</i> <sup>37</sup>	The Netherlands	Cross-sectional	High	178 (110 brf, 68 brm)	272+651 no GD	GnRH-a	Externalising problems (YSR)	N/A	No difference between groups.
Carmichael <i>et al</i> <sup>55</sup>	UK	Pre-post	Moderate	44 (19 brf, 25 brm)	N/A	GnRH-a	Externalising problems (CBCL/YSR)	12 m, 24 m, 36 m	No change over time.
de Vries <i>et al</i> <sup>24</sup>	The Netherlands	Pre-post	Moderate	70 (37 brf, 33 brm)	N/A	GnRH-a	Externalising problems (CBCL/YSR)	Before CSH start (range 0.4–5.1 y)	Small decrease (improvement).
<b>Psychological functioning/psychopathology</b>									
Carmichael <i>et al</i> <sup>55</sup>	UK	Pre-post	Moderate	44 (19 brf, 25 brm)	N/A	GnRH-a	Psychological functioning (total CBCL/YSR)	12 m, 24 m, 36 m	No change over time.
de Vries <i>et al</i> <sup>24</sup>	The Netherlands	Pre-post	Moderate	70 (37 brf, 33 brm)	N/A	GnRH-a	Psychological functioning (total CBCL/YSR)	Before CSH start (range 0.4–5.1 y)	Small decrease (improvement).
<b>Suicidality/Self-harm</b>									
van der Miesen <i>et al</i> <sup>37</sup>	The Netherlands	Cross-sectional	High	178 (110 brf, 68 brm)	272+651 no GD	GnRH-a	Self-harm/suicidality (YSR item 18 and 91)	N/A	Less self-harm/suicidality in those treated, although similar to group with no GD.

Continued

Table 2 Continued

Study	Country	Study design	Study quality	Treated sample	Comparator	Intervention	Outcome (measure)	Follow-up specific to outcome	Summary of study results
Carmichael <i>et al</i> <sup>55</sup>	UK	Pre-post	Moderate	44 (19 brf, 25 brm)	N/A	GnRH-a	Self-harm/suicidality (YSR item 18 and 91)	12 m, 24 m, 36 m	No change over time.
Other									
de Vries <i>et al</i> <sup>24</sup>	The Netherlands	Pre-post	Moderate	70 (37 brf, 33 brm)	N/A	GnRH-a	Anger (STAXI)	Before CSH start (range 0.4–5.1 y)	No change.
<b>Psychosocial outcomes</b>									
Psychosocial functioning									
Costa <i>et al</i> <sup>56</sup>	UK	Cohort	Moderate	60 (brm:brf ratio 1:1.7)	61+169 no GD	GnRH-a	Psychosocial functioning (CGAS)	6 m, 12 m, 18 m (GnRH-a initiated at 6 m)	Both groups improved after 6 m and 12 m of psychological care. At 18 m, treated group improved further, untreated remained the same.
Carmichael <i>et al</i> <sup>55</sup>	UK	Pre-post	Moderate	44 (19 brf, 25 brm)	N/A	GnRH-a	Psychosocial functioning (CGAS)	12 m, 24 m, 36 m	No change over time.
de Vries <i>et al</i> <sup>24</sup>	The Netherlands	Pre-post	Moderate	70 (37 brf, 33 brm)	N/A	GnRH-a	Psychosocial functioning (CGAS)	Before CSH start (range 0.4–5.1 y)	No clinically significant change.
Quality of life									
Carmichael <i>et al</i> <sup>55</sup>	UK	Pre-post	Moderate	44 (19 brf, 25 brm)	N/A	GnRH-a	Quality of life (Kidscreen-52)	12 m, 24 m	No change over time.
Peer-relations									
van der Miesen <i>et al</i> <sup>37</sup>	The Netherlands	Cross-sectional	High	178 (110 brf, 68 brm)	272+651 no GD	GnRH-a	Poor peer-relations (YSR items 25, 38 and 48)	N/A	Fewer problems in those treated, but more compared with adolescents with no GD.
<b>Cognitive/neurodevelopmental outcomes</b>									
Strang <i>et al</i> <sup>51</sup>	UK	Cross-sectional	Moderate	14 (brs not reported)	58+52 CSH	GnRH-a	Executive functioning (BRIEF Global Executive Composite)	N/A	No change in those treated with puberty suppression for <1 year. Worse functioning in those treated for longer (although some may have been taking CSH).
Russell <i>et al</i> <sup>69</sup>	UK	Pre-post	Moderate	95 (57 brf, 38 brm)	N/A	GnRH-a	Features of autism spectrum condition (SRS)	12 m	No change.
BDI, Beck's Depression Inventory; BIS, Body Image Scale; brf, birth-registered females; BRIEF, Behaviour Rating Inventory of Executive Function; brm, birth-registered males; CBCL, Child Behaviour Checklist; CGAS, Children's Global Assessment Scale; CSH, cross-sex hormones; GD, gender dysphoria; GnRH-a, gonadotropin-Releasing Hormone analogues; m, months; N/A, not applicable; SRS, Social Responsiveness Scale; STAI, State-Trait Anxiety Inventory; STAXI, State-Trait Anger Expression Inventory; UGDS, Utrecht Gender Dysphoria Scale; y, years; YSR, youth self-report.									

experiencing gender dysphoria/incongruence. However, there were considerably fewer participants included at final follow-up.

There was no change in quality of life pre-post,<sup>55</sup> and treated adolescents had better peer-relations compared with adolescents under assessment at a gender service but poorer peer-relations than adolescents not experiencing gender dysphoria/incongruence.<sup>37</sup>

### Cognitive/neurodevelopmental outcomes

One cross-sectional study measured executive functioning and found no difference between adolescents who were treated for <1 year compared with those not treated, but worse executive functioning in those treated for >1 year compared with those not treated.<sup>51</sup> A pre-post study found no differences in features typically associated with autism spectrum condition after treatment (table 2).<sup>59</sup>

### Physical health outcomes

#### Bone health

Five studies found decreases in bone mineral apparent density and z-scores pre-post treatment; however, absolute measures generally remained stable or increased/decreased slightly.<sup>29 32 34 55 58</sup> Results were similar across birth-registered males and females.<sup>29 32 55 58</sup> One study considered timing of treatment, and found similar decreases among those starting GnRH-a in early or late puberty (table 3).<sup>32</sup>

#### Cardiometabolic health

Twelve pre-post studies measured body mass index (BMI), and in 10 studies there was no evidence of a clinically significant change in BMI and/or BMI SD score.<sup>29 30 32 34 55 57 65 67-69</sup> In one study, BMI increased for birth-registered males but not females.<sup>58</sup> Another study found BMI increased for birth-registered females who started GnRH-a in early puberty or mid-puberty, and birth-registered males in early puberty.<sup>36</sup>

Three studies assessed cholesterol markers, one after GnRH-a (no changes),<sup>34</sup> one after cyproterone acetate (decrease in high-density lipoprotein (HDL) and triglycerides)<sup>67</sup> and one after lynestrenol (decrease in HDL, increase in low-density lipoprotein).<sup>65</sup> Three studies assessing GnRH-a reported blood pressure: two found similar systolic and diastolic blood pressure before and after treatment,<sup>34 68</sup> and one found a non-clinically significant increase in diastolic but not systolic blood pressure.<sup>69</sup> Two studies measured markers of diabetes (fasting glucose, HbA1c and/or insulin) and noted no changes.<sup>65 67</sup>

#### Other physiological parameters

Five pre-post studies assessed other parameters from blood tests undertaken at baseline and follow-up,<sup>30 31 34 65 67</sup> three in those treated with GnRH-a,<sup>30 31 34</sup> one lynestrenol<sup>65</sup> and one cyproterone acetate.<sup>67</sup> Measurements included haemoglobin count (n=3), haematocrit percentage (n=3), creatinine (n=4), aspartate aminotransferase (n=3), alanine aminotransferase (n=3),  $\gamma$ -glutamyl transferase (n=1), alkaline phosphatase (n=2), prolactin (n=2), free thyroxine (n=3), thyroid-stimulating hormone (n=3), sex hormone binding globulin (n=3), vitamin D levels (n=1), dehydroepiandrosterone sulfate (n=3) and androstenedione (n=2). For most outcomes, no changes were reported. Where there were changes, these were not consistent in direction across studies.

One pre-post study assessing GnRH-a reported QTc prolongation,<sup>64</sup> and found no change in mean QTc, with no participants outside normal range.

### Side effects

A cohort study of GnRH-a reported side effects including mild headaches or hot flushes (~20%) and moderate/severe headaches or hot flushes, mild fatigue, mood swings, weight gain and sleep problems (<10%) (table 3).<sup>55</sup>

Two studies assessed other medications and reported headaches and hot flushes as common and an increase in acne in a sample of birth-registered females receiving lynestrenol,<sup>65</sup> and complaints of fatigue in birth-registered males receiving cyproterone acetate.<sup>67</sup>

### Puberty suppression

#### Hormone levels

Hormone levels were reported in nine studies of GnRH-a (two cohort,<sup>49 50</sup> seven pre-post<sup>30 34 36 48 55 68 69</sup>), two in birth-registered females,<sup>34 69</sup> one in birth-registered males<sup>68</sup> and six including both (table 4).<sup>30 36 48-50 55</sup>

Five studies reported decreases in luteinising hormone, follicle-stimulating hormone, oestradiol and testosterone after receiving GnRH-a.<sup>30 34 48 68 69</sup> Another study, which reported luteinising and follicle-stimulating hormones, also found decreases in both pre-post.<sup>55</sup> One study reported that where baseline levels were high due to puberty starting, decreases were reported in testosterone and oestradiol.<sup>36</sup> One cohort study reporting pre-post data found smaller decreases in luteinising hormone, follicle-stimulating hormone, oestradiol and testosterone compared with other studies; however, it included a younger population, some of who were likely prepubertal.<sup>50</sup> The other cohort study included a comparator of adolescents with precocious puberty and found similar decreases in luteinising hormone and oestradiol.<sup>49</sup>

One pre-post study of lynestrenol (birth-registered females) found a decrease in luteinising hormones but not follicle-stimulating hormone, oestradiol or testosterone.<sup>65</sup> One study of cyproterone acetate (birth-registered males) found no changes in luteinising hormone, follicle-stimulating hormone or oestradiol, but a decrease in total testosterone.<sup>67</sup>

#### Pubertal progression

Puberty development was reported in four studies (two cohort, two pre-post).<sup>30 35 49 67</sup> One only included birth-registered males,<sup>67</sup> and three included both birth-registered males and females.<sup>30 35 49</sup>

A cohort study assessing GnRH-a reported clinical pubertal escape in 2/21 adolescents treated for gender dysphoria/incongruence, in the form of breast enlargement or testicular enlargement together with deepening of voice, compared with no children treated for precocious puberty.<sup>49</sup> A pre-post study reported a decrease in testicular volume in birth-registered males, but unclear results with regard to breast development in birth-registered females (most started treatment at Tanner stage 4-5).<sup>30</sup> A pre-post study of birth-registered males using cyproterone acetate reported decreases in facial shaving and spontaneous erections.<sup>67</sup>

A cohort study assessed whether secondary sex characteristics differed depending on receipt or timing of GnRH-a, and whether this affected which surgical interventions/techniques were later used.<sup>35</sup> The study found breast size was smallest in birth-registered females who received GnRH-a in Tanner stage 2/3 and largest in untreated participants. Those treated early in puberty were less likely to require a mastectomy and when surgery was required it was less burdensome. In birth-registered males, penile length was greater in those who received GnRH-a

**Table 3** Physical health outcomes and side effects

Study	Country	Study design	Study quality	Treated sample	Intervention	Outcome (measure)	Follow-up specific to outcome	Summary of study results
<b>Physical health outcomes</b>								
<b>Bone health</b>								
Carmichael <i>et al</i> <sup>65</sup>	UK	Pre-post	Moderate	44 (19 brf, 25 brm)	GnRH-a	BMD and BMC (hip, lumbar, spine). Absolute values and z-scores	12 m, 24 m, 36 m	Between baseline and 12 months, there was an increase in absolute measures of bone health, but z-scores decreased.
Joseph <i>et al</i> <sup>68</sup>	UK	Pre-post	Moderate	70 (39 brf, 31 brm)	GnRH-a	BMD, BMAD. Absolute values and z-scores	12 m, 24 m, 36 m	Absolute measures of bone health remained constant, but z-scores decreased.
Klink <i>et al</i> <sup>29</sup>	The Netherlands	Pre-post	Moderate	34 (19 brf, 15 brm)	GnRH-a	aBMD and BMAD (absolute, z-scores using natal sex)	Before CSH start (mean 1.3 y for brm, 1.5 y for brf, range 0.25–5.2 y)	Absolute measures of bone health remained constant, but z-scores decreased.
Schagen <i>et al</i> <sup>32</sup>	The Netherlands	Pre-post	Moderate	121 (70 brf, 51 brm)	GnRH-a	aBMD and BMAD (absolute, z-scores using natal sex), serum bone markers	24 m	Absolute measures of bone health increased, but z-scores decreased (decreases similar in groups who started GnRH-a in early puberty and mid-puberty).
Stoffers <i>et al</i> <sup>34</sup>	The Netherlands	Pre-post	Moderate	62 brf	GnRH-a	BMD, BMAD (absolute, z-scores using natal sex)	Before CSH start (median 8 m, range 3–39)	Absolute measures of bone health and z-scores decreased.
<b>BMI</b>								
Carmichael <i>et al</i> <sup>65</sup>	UK	Pre-post	Moderate	44 (19 brf, 25 brm)	GnRH-a	BMI z-score (reference population for age and natal sex)	12 m, 24 m, 36 m	No evidence for change in BMI z-score.
Ghelani <i>et al</i> <sup>67</sup>	UK	Pre-post	Moderate	36 (25 brf, 11 brm)	GnRH-a	BMI SD score (reference sex unspecified)	6 m, 12 m	No evidence for change in BMI SD score.
Joseph <i>et al</i> <sup>68</sup>	UK	Pre-post	Moderate	70 (39 brf, 31 brm)	GnRH-a	BMI	12 m, 24 m, 36 m	BMI increased over time in birth-registered males.
Klink <i>et al</i> <sup>29</sup>	The Netherlands	Pre-post	Moderate	34 (19 brf, 15 brm)	GnRH-a	BMI and BMI SD score (in reference to natal sex)	Before CSH start (mean 1.3 y for brm, 1.5 y for brf, range 0.25–5.2 y)	BMI and BMI SD score remained the same.
Perl <i>et al</i> <sup>69</sup>	Israel	Pre-post	Moderate	15 brf	GnRH-a	BMI and BMI SD score (reference sex unspecified)	Single (end of GnRH-a, mean 3 m SD 1)	No evidence for clinically significant change in BMI or BMI SD score.
Perl <i>et al</i> <sup>68</sup>	Israel	Pre-post	Moderate	19 brm	GnRH-a	BMI and BMI SD score (reference sex unspecified)	Single (end of GnRH-a, mean 9 m SD 6)	No evidence for change in BMI or BMI SD score.
Schagen <i>et al</i> <sup>30</sup>	The Netherlands	Pre-post	Moderate	116 (67 brf, 49 brm)	GnRH-a	BMI and BMI SD score (reference sex used unspecified)	12 m, 24 m, 36 m	No evidence for clinically significant change in BMI or BMI SD score.
Schagen <i>et al</i> <sup>32</sup>	The Netherlands	Pre-post	Moderate	121 (70 brf, 51 brm)	GnRH-a	BMI	24 m	No evidence for change in BMI.
Stoffers <i>et al</i> <sup>34</sup>	The Netherlands	Pre-post	Moderate	62 brf	GnRH-a	BMI and BMI SD score (reference unspecified)	Before CSH start (median 8 m, range 3–39)	No evidence for change in BMI or SD score.
Tack <i>et al</i> <sup>65</sup>	Belgium	Pre-post	Moderate	38 brf	Lynestrenol	BMI and BMI SD score (reference population for natal sex)	6 m, 12 m	No evidence for change in BMI or BMI SD score.
Tack <i>et al</i> <sup>67</sup>	Belgium	Pre-post	Moderate	27 brm	Cyproterone acetate	BMI and BMI SD score (in reference to natal sex)	6 m, 12 m	No evidence for change in BMI SD score.
van der Loos <i>et al</i> <sup>36</sup>	The Netherlands	Pre-post	Moderate	322 (106 brm, 216 brf)	GnRH-a	BMI	Before CSH start (mean follow-up between 0.9 and 3.9 y)	BMI increased for brf who started in early puberty and mid-puberty. For brm, BMI there was an increase in the early puberty group. No change in the late-puberty group.
<b>Blood pressure</b>								
Perl <i>et al</i> <sup>69</sup>	Israel	Pre-post	Moderate	15 brf	GnRH-a	Systolic and diastolic blood pressure	Single (end of GnRH-a, mean 3 m SD 1)	Systolic blood pressure remained the same, whereas diastolic blood pressure increased, although not clinically significant.

Continued

**Table 3** Continued

Study	Country	Study design	Study quality	Treated sample	Intervention	Outcome (measure)	Follow-up specific to outcome	Summary of study results
Perl <i>et al</i> <sup>68</sup>	Israel	Pre-post	Moderate	19 brm	GnRH-a	Systolic and diastolic blood pressure	Single (end of GnRH-a, mean 9 m SD 6)	Systolic and diastolic blood pressure remained the same.
Stoffers <i>et al</i> <sup>34</sup>	The Netherlands	Pre-post	Moderate	62 brf	GnRH-a	Systolic and diastolic blood pressure	Before CSH start (median 8 m, range 3–39)	Systolic and diastolic blood pressure remained the same.
Metabolic measures								
Stoffers <i>et al</i> <sup>34</sup>	The Netherlands	Pre-post	Moderate	62 brf	GnRH-a	Total cholesterol, HDL, LDL, triglycerides	Before CSH start (median 8 m, range 3–39)	No evidence for a change in any measure.
Tack <i>et al</i> <sup>65</sup>	Belgium	Pre-post	Moderate	38 brf	Lynestrenol	Total cholesterol, triglycerides, HDL, LDL, fasting insulin, HbA1c	6 m, 12 m	No evidence for a change in any measure, except for a decrease in HDL and increase in LDL.
Tack <i>et al</i> <sup>67</sup>	Belgium	Pre-post	Moderate	27 brm	Cyproterone acetate	Triglycerides, total cholesterol, HDL, LDL, HbA1c, glucose, insulin	6 m, 12 m	There was a decrease in HDL and triglycerides.
Other physical parameters								
Schagen <i>et al</i> <sup>30</sup>	The Netherlands	Pre-post	Moderate	116 (67 brf, 49 brm)	GnRH-a	ALT, AST, ALP, $\gamma$ -glutamyl transferase, creatinine	3 m, 6 m, 12 m	There was a decrease in alkaline phosphate (both sexes) and creatinine (brf only). No changes were reported in AST, $\gamma$ -glutamyl and ALT (narrative—no data).
Stoffers <i>et al</i> <sup>34</sup>	The Netherlands	Pre-post	Moderate	62 brf	GnRH-a	SHBG, TSH, prolactin, free thyroxine, DHEAS, A4, haemoglobin, haematocrit, creatinine, ALP, vitamin D, ureum	Before CSH start (median 8 m, range 3–39)	There was an increase in vitamin D levels and a decrease in prolactin levels—no change for other measures.
Tack <i>et al</i> <sup>65</sup>	Belgium	Pre-post	Moderate	38 brf	Lynestrenol	Haemoglobin, haematocrit, creatinine, ALT, AST, TSH, free thyroxine, anti-Müllerian hormone, SHBG	6 m, 12 m	There were increases in haemoglobin and haematocrit and a decrease in SHBG. Increases in free thyroxine levels, creatinine and ALT were reported.
Tack <i>et al</i> <sup>67</sup>	Belgium	Pre-post	Moderate	27 brm	Cyproterone acetate	DHEAS, haemoglobin, haematocrit, creatinine, AST, ALT, prolactin, TSH, free thyroxine, SHBG	6 m, 12 m	There was an increase in prolactin and free thyroxine levels, and a decrease in haemoglobin and haematocrit. No change in other measures.
Schagen <i>et al</i> <sup>31</sup>	The Netherlands	Pre-post	Moderate	127 (73 brf, 54 brm)	GnRH-a	DHEAS and A4	12 m, 24 m	DHEAS increased in brf and increased slightly in brm. A4 decreased in brf and remained constant in brm.
Waldner <i>et al</i> <sup>64</sup>	Canada	Pre-post	Moderate	33 (23 brf, 10 brm)	GnRH-a	Proportion with clinically significant QTc prolongation (defined as QTc >460 ms)	Single (>6 weeks after initiation of treatment)	There was no change in the mean QTc over time. At follow-up, no participants were in the clinical range >(460 ms). Just under 25% had a QTc between 440 and 460 ms.
Side effects								
Carmichael <i>et al</i> <sup>55</sup>	UK	Pre-post	Moderate	44 (19 brf, 25 brm)	GnRH-a	Patient-reported side effects	12 m, 24 m, 36 m	Mild headaches or hot flushes common (~20%). Moderate/Severe headaches or hot flushes, mild fatigue, mood swings, weight gain, sleep problems less common (<10%).
Tack <i>et al</i> <sup>65</sup>	Belgium	Pre-post	Moderate	38 brf	Lynestrenol	Patient-reported side effects	6 m, 12 m	Headaches and hot flushes were common, reported increase in acne and metrorrhagia was also reported—no numbers given.
Tack <i>et al</i> <sup>67</sup>	Belgium	Pre-post	Moderate	27 brm	Cyproterone acetate	Patient-reported side effects	6 m, 12 m	Complaints of fatigue in 37% and emotionality in ~10%.

A4, androstenedione; aBMD, areal bone mineral density; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMAD, bone mineral apparent density; BMC, bone mineral content; BMD, bone mineral density; BMI, body mass index; brf, birth-registered females; brm, birth-registered males; CSH, cross-sex hormones; DHEAS, dehydroepiandrosterone sulfate; GnRH-a, gonadotropin-releasing hormone analogues; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; m, months; QTc, heart-rate corrected QT interval; SHBG, sex hormone binding globulin; TSH, thyroid-stimulating hormone; y, years.

**Table 4** Puberty suppression outcomes

Study	Country	Study design	Study quality	Treated sample	Comparator	Intervention	Outcome (measure)	Follow-up specific to outcome	Summary of study results
Hormone levels									
Pine-Twaddell <i>et al</i> <sup>49</sup>	USA	Cohort	Moderate	42 (22 brf, 20 brm)	7 with central precocious puberty	GnRH-a	Testosterone, oestradiol, LH	Single (range 17–65 m)	LH decreased to similar levels at follow-up in both groups. Oestradiol decreased in brf in both groups.
Schulmeister <i>et al</i> <sup>50</sup>	USA	Cohort	Moderate	55 (29 brf, 26 brm)	226 no GD	GnRH-a	Testosterone, oestradiol, LH, FSH	6 m, 12 m	For brf, all decreased at follow-up. Decreases were smaller in brm, but with larger decreases in upper limit of the IQR.
Carmichael <i>et al</i> <sup>55</sup>	UK	Pre-post	Moderate	44 (19 brf, 25 brm)	N/A	GnRH-a	Testosterone, oestradiol, LH, FSH	12 m, 24 m, 36 m	Decreases in LH and FSH observed over time. Oestradiol and testosterone not reported (full suppression reported).
Olson-Kennedy <i>et al</i> <sup>48</sup>	USA	Pre-post	Moderate	66 (34 brf, 32 brm)	N/A	GnRH-a	Testosterone, oestradiol, LH, FSH	Single (range 2–12 m)	Decreases reported in all outcomes.
Perl <i>et al</i> <sup>69</sup>	Israel	Pre-post	Moderate	15 brf	N/A	GnRH-a	Testosterone, oestradiol, LH, FSH	Single (end of GnRH-a, mean 3 m SD 1)	Decreases reported in all outcomes.
Perl <i>et al</i> <sup>68</sup>	Israel	Pre-post	Moderate	19 brm	N/A	GnRH-a	Testosterone, oestradiol, LH, FSH	Single (end of GnRH-a, mean 9 m SD 6)	Decreases reported in all outcomes.
Schagen <i>et al</i> <sup>30</sup>	The Netherlands	Pre-post	Moderate	116 (67 brf, 49 brm)	N/A	GnRH-a	Testosterone, oestradiol, LH, FSH	3 m, 6 m, 12 m	Decreases reported in all outcomes.
Stoffers <i>et al</i> <sup>34</sup>	The Netherlands	Pre-post	Moderate	62 brf	N/A	GnRH-a	Testosterone, oestradiol, LH, FSH	Before CSH start (median 8 m, range 3–39)	Decreases reported in all outcomes.
Tack <i>et al</i> <sup>65</sup>	Belgium	Pre-post	Moderate	38 brf	N/A	Lynestrenol	Testosterone (total, free), oestradiol, LF, FSH	6 m, 12 m	A decrease was reported in LH, but no change was observed in FSH, oestradiol or testosterone.
Tack <i>et al</i> <sup>67</sup>	Belgium	Pre-post	Moderate	27 brm	N/A	Cyproterone acetate	Testosterone (total, free), oestradiol, LF, FSH	6 m, 12 m	No changes were reported in hormone levels, except for a decrease in total testosterone.
van der Loos <i>et al</i> <sup>36</sup>	The Netherlands	Pre-post	Moderate	322 (106 brm, 216 brf)	N/A	GnRH-a	Testosterone, oestradiol	Before CSH start (mean follow-up 0.9, 3.1 and 3.9 y)*	Where baseline levels were high due to puberty starting, decreases reported in all outcomes.
Pubertal progression									
Pine-Twaddell <i>et al</i> <sup>49</sup>	USA	Cohort	Moderate	42 (22 brf, 20 brm)	7 CPP	GnRH-a	Tanner stage progression (physical examination)	Single (range 17–65 m)	Clinical pubertal escape was reported in 2/21 participants (breast enlargement in one case and in another case testicular enlargement and voice change).
van de Griff <i>et al</i> <sup>35</sup>	The Netherlands	Cohort	Moderate	200 (134 brf, 66 brm)	100	GnRH-a	Breast and genital characteristics (clinical examination)	At initiation of surgery (after CSH)	Tanner stage 2/3 treatment resulted in smaller breast size in brf and lower average penile length and fewer testes descended in brm, compared with Tanner stage 4/5 or no GnRH-a.
van de Griff <i>et al</i> <sup>35</sup>	The Netherlands	Cohort	Moderate	200 (134 brf, 66 brm)	100	GnRH-a	Needs for future surgery (clinical examination, surgery performed)	At initiation of surgery (after CSH)	Tanner stage 2/3 treatment resulted in need for fewer and less burdensome mastectomies in brf, but more genital surgery in brm, compared with Tanner stage 4/5 or no treatment.
Schagen <i>et al</i> <sup>30</sup>	The Netherlands	Pre-post	Moderate	116 (67 brf, 49 brm)	N/A	GnRH-a	Tanner stage by physical examination	3 m, 6 m, 12 m, 24 m	In brm, testicular volume decreased for 43/49 participants during GnRH-a treatment. Results unclear for brf, most of who started treatment in Tanner stage 4/5.
Tack <i>et al</i> <sup>67</sup>	Belgium	Pre-post	Moderate	27 brm	N/A	Cyproterone acetate	Puberty development (physical changes)	6 m, 12 m	>50% brm reported decreased facial shaving. Some reported decreased spontaneous erections (numbers not reported). Breast development noted in ~30% of brf.
Menstrual suppression									
Pine-Twaddell <i>et al</i> <sup>49</sup>	USA	Cohort	Moderate	42 (22 brf, 20 brm)	7 CPP	GnRH-a	Suppression of menstruation	Single (range 17–65 m)	No participants in the intervention group reported pubertal escape in the form of menstruation or spotting.
Carmichael <i>et al</i> <sup>55</sup>	UK	Pre-post	Moderate	44 (19 brf, 25 brm)	N/A	GnRH-a	Suppression of menstruation	12 m, 24 m, 36 m	All birth-registered females reported amenorrhoea in the 3 months after starting GnRH-a treatment.
Schagen <i>et al</i> <sup>30</sup>	The Netherlands	Pre-post	Moderate	116 (67 brf, 49 brm)	N/A	GnRH-a	Suppression of menstruation	12 m	All birth-registered females who had started menses experienced full suppression.

Continued

Table 4 Continued

Study	Country	Study design	Study quality	Treated sample	Comparator	Intervention	Outcome (measure)	Follow-up specific to outcome	Summary of study results
Height/Growth									
Schulmeister <i>et al</i> <sup>50</sup>	USA	Cohort	Moderate	55 (29 brf, 26 brm)	226 no GD	GnRH-a	Height velocity	6 m, 12 m	After controlling for mid-age, height velocity in participants using GnRH-a was similar to the cisgender comparison.
Carmichael <i>et al</i> <sup>55</sup>	UK	Pre-post	Moderate	44 (19 brf, 25 brm)	N/A	GnRH-a	Height z-score	12 m, 24 m, 36 m	No change in height z-score over time.
Ghelani <i>et al</i> <sup>67</sup>	UK	Pre-post	Moderate	36 (25 brf, 11 brm)	N/A	GnRH-a	Height SD score (reference sex unspecified)	6 m, 12 m	Decrease over time observed in height SD score for brm. No change observed in brf.
Joseph <i>et al</i> <sup>58</sup>	UK	Pre-post	Moderate	70 (39 brf, 31 brm)	N/A	GnRH-a	Height	12 m, 24 m, 36 m	Height increased over time for both brm and brf.
Klink <i>et al</i> <sup>29</sup>	The Netherlands	Pre-post	Moderate	34 (19 brf, 15 brm)	N/A	GnRH-a	Height and height SD score (reference to natal sex)	Before CSH start (mean 1.3 y for brm, 1.5 y for brf, range 0.25–5.2 y)	Height increased for both brm and brf. Height SD score decreased for brm but not for brf.
Schagen <i>et al</i> <sup>30</sup>	The Netherlands	Pre-post	Moderate	116 (67 brf, 49 brm)	N/A	GnRH-a	Height and height SD score (reference sex unspecified)	12 m	Height increased for both brm and brf. Height SD score decreased for both brm and brf.
Schagen <i>et al</i> <sup>32</sup>	The Netherlands	Pre-post	Moderate	121 (70 brf, 51 brm)	N/A	GnRH-a	Height	24 m	Height increased.
Stoffers <i>et al</i> <sup>34</sup>	The Netherlands	Pre-post	Moderate	62 brf	N/A	GnRH-a	Height, height SD score (reference to natal sex and affirmed gender)	Before CSH start (median 8 m, range 3–39)	No substantial change in average height. Height SD score decreased against male reference population, and no change against female reference population.
Tack <i>et al</i> <sup>65</sup>	Belgium	Pre-post	Moderate	38 brf	N/A	Lynestrenol	Height	6 m, 12 m	Height increased over time.
Tack <i>et al</i> <sup>67</sup>	Belgium	Pre-post	Moderate	27 brm	N/A	Cyproterone acetate	Height SD score (reference using natal sex)	6 m, 12 m	Height SD score decreased over time.
van der Loos <i>et al</i> <sup>36</sup>	The Netherlands	Pre-post	Moderate	322 (106 brm, 216 brf)	N/A	GnRH-a	Height	Before CSH start (mean follow-up 0.9, 3.1 and 3.9 y)*	Height increased in the early puberty and mid-puberty groups.
Body composition									
Ghelani <i>et al</i> <sup>67</sup>	UK	Pre-post	Moderate	36 (11 brm, 25 brf)	N/A	GnRH-a	Body composition (lean mass SD score). Reference sex unspecified	6 m, 12 m	In both sexes, the lean mass SD score decreased over time.
Schagen <i>et al</i> <sup>30</sup>	The Netherlands	Pre-post	Moderate	116 (67 brf, 49 brm)	N/A	GnRH-a	Body composition (lean body mass percentage)	12 m	In both sexes, lean body mass percentage decreased.
Schagen <i>et al</i> <sup>30</sup>	The Netherlands	Pre-post	Moderate	116 (67 brf, 49 brm)	N/A	GnRH-a	Body composition (fat percentage)	12 m	In both sexes, fat percentage increased.
Bone geometry									
van der Loos <i>et al</i> <sup>36</sup>	The Netherlands	Pre-post	Moderate	322 (106 brm, 216 brf)	N/A	GnRH-a	Subperiosteal width and endocortical diameter of hip bone	Before CSH start (mean follow-up 0.9, 3.1 and 3.9 y)*	In brm, both measures increased in early puberty and mid-puberty groups. In brf, both increased in the early puberty group only. No change in late-puberty group for either.

\*Sample divided into three groups, those starting GnRH-a in early puberty, mid-puberty and late puberty. Mean follow-up presented for each group, respectively.

brf, birth-registered females; brm, birth-registered males; CSH, cross-sex hormones; FSH, follicle-stimulating hormone; GD, gender dysphoria; GnRH-a, gonadotropin-releasing hormone analogues; LH, luteinising hormone; m, months; N/A, not applicable; y, years.

at Tanner stage 4/5 compared with Tanner stage 2/3, and greatest in untreated participants.<sup>35</sup> Those who received GnRH-a early required more invasive vaginoplasty techniques than those who received it later or not at all.

### Menstrual suppression

Three studies (one cohort, two pre-post) measured menstrual suppression in birth-registered females, and found full suppression at follow-up,<sup>30 49 55</sup> which was similar to the effect seen in those with precocious puberty in the cohort study.<sup>49</sup>

### Height/Growth

Eleven studies (1 cohort,<sup>50</sup> 10 pre-post<sup>29 30 32 34 36 55 57 58 65 67</sup>) reported height, nine after GnRH-a,<sup>29 30 32 34 36 50 55 57 58</sup> one linyestrenol<sup>65</sup> and one cyproterone acetate.<sup>67</sup> The cohort study found a similar height velocity between the GnRH-a group and adolescent controls.<sup>50</sup> Six studies reported height Z or SD score<sup>29 30 34 55 57 67</sup> with two studies finding no change,<sup>34 55</sup> two a decrease for birth-registered males but not females,<sup>29 57</sup> one a decrease across birth-registered males and females<sup>30</sup> and one a decrease in birth-registered males with cyproterone acetate.<sup>67</sup> Absolute measures of height generally increased slightly or remained the same.<sup>29 30 32 34 36 58 65 67</sup>

### Body composition

Two studies reported changes in body composition pre-post,<sup>30 57</sup> reporting a significant decrease in lean mass SD score<sup>57</sup> and percentage<sup>30</sup> in males and females. One also measured body fat percentage and reported significant increases in both groups.<sup>30</sup>

### Bone geometry

One pre-post study measured the subperiosteal width and endocortical diameter of the hip bone and found that in birth-registered males these increased in those starting GnRH-a in early puberty and mid-puberty, but only in the early puberty group for birth-registered females.<sup>36</sup>

## DISCUSSION

This systematic review identified 50 studies reporting outcomes relating to puberty suppression in adolescents experiencing gender dysphoria/incongruence. No high-quality studies using an appropriate design were identified, and only four measured gender dysphoria as an outcome. Only 5 of the 11 cohort studies, which were the only studies to compare groups over time, were rated as moderate quality.<sup>35 40 49 50 56</sup>

There was evidence from multiple mainly pre-post studies that puberty suppression exerts its expected physiological effect, as previously demonstrated in children with precocious puberty.<sup>73</sup> In adolescents experiencing gender dysphoria/incongruence, puberty suppression is initiated at different stages of puberty,<sup>74</sup> and two studies found that the effects on secondary sex characteristics may vary depending on whether treatment is initiated in early puberty versus mid-puberty, with potentially different outcomes for birth-registered males and females.<sup>30 35</sup> Multiple studies also found that bone density is compromised during puberty suppression, and gains in height may lag behind that seen in other adolescents. High-quality research is needed to confirm these findings; however, these potential risks should be explained to adolescents considering puberty suppression.

These findings add to other systematic reviews in concluding there is insufficient and/or inconsistent evidence about the effects of puberty suppression on gender dysphoria, body satisfaction,

psychological and psychosocial health, cognitive development, cardiometabolic risk and fertility.<sup>11–16</sup> Regarding psychological health, one recent systematic review<sup>14</sup> reported some evidence of benefit while others have not. The results in this review found no consistent evidence of benefit. Inclusion of only moderate-quality to high-quality studies may explain this difference, as 8 of the 12 studies reporting psychological outcomes were rated as low-quality.

The lack of representativeness of samples and comparability of selected control groups were key concerns across studies. Only one study attempted to compare puberty suppression with psychosocial care, which is the only other treatment offered for gender dysphoria/incongruence in childhood, and this included a small sample, limited analyses, and little detail about the intervention.<sup>56</sup> Other studies lacked information about any psychological care provided to participants, and in studies that included a comparator there was limited information about any differences between groups. Large, well-designed studies with appropriate comparators that enable long-term outcomes of puberty suppression to be measured are needed.

Many studies reported effects of both puberty suppressants and hormones used in later adolescence for feminisation/masculinisation. In adolescents, GnRH-a often continues during hormone treatment,<sup>74</sup> or for adolescents who do not receive puberty suppression, GnRH-a or other anti-androgens may be offered at initiation of hormones.<sup>66</sup> This makes long-term follow-up of puberty suppression difficult to assess, including any differences between the types of interventions that are offered and when these are initiated, and the few studies reporting long-term outcomes either did not control for this or reported overall effects for both interventions. Although recent studies suggest nearly all adolescents who receive puberty suppression go on to feminising/masculinising hormones,<sup>74–76</sup> research is still needed to assess whether suppression will have any lasting effects for those who do not. Aggregation of studies reporting proportions of adolescents who progress to hormones and reasons for discontinuation would also offer useful insights.

Included studies assessed different outcomes across various outcome domains and employed multiple different measures. Agreement about the primary aim and related core outcomes of puberty suppression in this population would help to ensure studies measure key outcomes and facilitate future aggregation of evidence. Expert consensus recommendations to guide the methods and domains for assessing the neurodevelopmental effects of puberty suppression have been developed<sup>77</sup>; however, there is currently no agreement across other outcome domains.

### Strengths and limitations

Strengths include a published protocol with robust search strategies, use of PRISMA guidelines and comprehensive synthesis of moderate and high quality studies. Poor reporting across studies may have resulted in moderate-quality studies being rated low-quality and excluded from synthesis. As searches were conducted up to April 2022, this review does not include more recently published studies. However, the findings are in line with previous reviews despite the inclusion of numerous additional studies. In an update of the National Institute for Health and Care Excellence evidence review of GnRH-a performed in April 2023,<sup>78</sup> nine additional studies were identified, two of which they felt might materially affect their conclusions.<sup>72 74</sup> One was already included in this review,<sup>72</sup> and the other examined treatment trajectories which was not an outcome of interest.<sup>74</sup>

Of other studies that we are aware have been published since April 2022 until January 2024, very few used a cohort design or an appropriate comparator and were of a similar low quality to moderate quality as the studies summarised in this review. Of those likely to contribute new data for synthesis, five examined physical growth and development,<sup>79–83</sup> one cardiometabolic health<sup>84</sup> and one psychological health.<sup>85</sup> The latter, a study from the US, found that adolescents who received puberty suppression before assessment for masculinising or feminising hormones had fewer symptoms of depression, anxiety, stress and suicidal thoughts compared with those who had not received puberty suppression. A sensitivity analysis found similar results, although no difference in suicidal thoughts.<sup>85</sup> Adding this study would provide no further clarity about whether puberty suppression improves psychological health due to the inconsistency of results between studies, and the limited high-quality research measuring these outcomes.

Two studies from the Netherlands found that height growth and bone maturation both decelerated during GnRH-a treatment,<sup>80–81</sup> and a third assessing only bone health found the same.<sup>83</sup> A Belgian study found stable height growth in birth-registered females but deceleration in birth-registered males.<sup>82</sup> These studies add strength to the conclusion that bone health and adult height may be compromised during GnRH-a, although like in previous studies the participants went on to receive masculinising or feminising hormones, and therefore the long-term outcomes of puberty suppression alone were not possible to determine.

Another new study, also from the Netherlands, assessed changes in body composition.<sup>79</sup> This found that in both birth-registered males and females lean mass z-scores decreased during puberty suppression and fat mass z-scores increased, although the rate and duration of change differed by birth-registered sex. These changes were also found in the two studies synthesised,<sup>30–57</sup> but as all three included no comparator uncertainty continues about the effect of puberty suppression on body composition.

A large study of adults in the US examined whether receipt of hormone interventions during adolescence was associated with cardiometabolic-related diagnoses, and for GnRH-a found no statistically significant differences for any diagnosis.<sup>84</sup> However, the study uses a retrospective cross-sectional design and is the only study to have examined cardiometabolic diagnoses, so no conclusions can be drawn about these outcomes.

To our knowledge, there are no additional moderate-quality or high-quality studies that have measured psychosocial or fertility outcomes, and only a single study assessing cognitive effects which measured a different outcome (white matter microstructure) to those included in this review.<sup>86</sup>

## Conclusions

There are no high-quality studies using an appropriate study design that assess outcomes of puberty suppression in adolescents experiencing gender dysphoria/incongruence. No conclusions can be drawn about the effect on gender-related outcomes, psychological and psychosocial health, cognitive development or fertility. Bone health and height may be compromised during treatment. High-quality research and agreement on the core outcomes of puberty suppression are needed.

**Contributors** LF, CEH, RH, TL and JT contributed to the conception of this review. RH, CEH, CH, AM and JT contributed to screening and selection. AM and JT completed data extraction. CEH, RH, AM and JT contributed to critical appraisal. CEH, AM and JT completed the synthesis and drafted the manuscript. All authors contributed to interpretation and reviewed and approved the manuscript prior to

submission. CEH accepts full responsibility for the finished work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

**Funding** This work was funded by NHS England to inform the Cass Review (Independent review of gender identity services for children and young people). The funder and Cass Review team had a role in commissioning the research programme but no role in the study conduct, interpretation or conclusion.

**Competing interests** None declared.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Commissioned; externally peer reviewed.

**Data availability statement** Data sharing not applicable as no datasets generated and/or analysed for this study.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iDs

Jo Taylor <http://orcid.org/0000-0001-5898-0900>

Catherine Elizabeth Hewitt <http://orcid.org/0000-0002-0415-3536>

## REFERENCES

- Thompson L, Sarovic D, Wilson P, *et al*. A PRISMA systematic review of adolescent gender Dysphoria literature: 1) epidemiology. *PLOS Glob Public Health* 2022;2:e0000245.
- Kaltiala R, Bergman H, Carmichael P, *et al*. Time trends in referrals to child and adolescent gender identity services: a study in four Nordic countries and in the UK. *Nord J Psychiatry* 2020;74:40–4.
- Thompson L, Sarovic D, Wilson P, *et al*. A PRISMA systematic review of adolescent gender Dysphoria literature: 2) mental health. *PLOS Glob Public Health* 2022;2:e0000426.
- Coleman E, Radix AE, Bouman WP, *et al*. Standards of care for the health of transgender and gender diverse people, version 8. *Int J Transgend Health* 2022;23:S1–259.
- Hembree WC, Cohen-Kettenis PT, Gooren L, *et al*. Endocrine treatment of gender-Dysphoric/gender-Incongruent persons: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2017;102:3869–903.
- de Vries ALC, Cohen-Kettenis PT. Clinical management of gender Dysphoria in children and adolescents: the Dutch approach. *J Homosex* 2012;59:301–20.
- The Swedish National Board of Health and Welfare. Care of children and young people with gender Dysphoria - national knowledge support with recommendations for the profession and decision makers. 2022. Available: <https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/kunskapsstod/2022-12-8302.pdf>
- Telfer MM, Tollit MA, Pace CC, *et al*. Australian standards of care and treatment guidelines for transgender and gender diverse children and adolescents. *Med J Aust* 2018;209:132–6.
- University of California San Francisco Gender Affirming Health Program. *Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People*. University of California San Francisco, 2016. Available: <https://transcare.ucsf.edu/guidelines>
- Medical treatment methods for Dysphoria associated with variations in gender identity in minors – recommendation. 2020. Available: <https://palveluvalikoima.fi/en/recommendations#genderidentity>
- National Institute for Health and Care Excellence (NICE). Evidence review: gonadotrophin releasing hormone analogues for children and adolescents with gender Dysphoria. 2020. Available: [https://cass.independent-review.uk/wp-content/uploads/2022/09/20220726\\_Evidence-review\\_GnRH-analogues\\_For-upload\\_Final.pdf](https://cass.independent-review.uk/wp-content/uploads/2022/09/20220726_Evidence-review_GnRH-analogues_For-upload_Final.pdf)
- Pasternack I, Söderström I, Saijonkari M, *et al*. Medical approaches to treatment of Dysphoria related to gender variations. A systematic review. 2019. Available: <https://app.box.com/s/y9u791np8v9gsunwgr2kqn8swd9vdtx>
- Ludvigsson JF, Adolfsson J, Höistad M, *et al*. A systematic review of hormone treatment for children with gender Dysphoria and recommendations for research.

- Acta Paediatrica* 2023;112:2279–92. 10.1111/apa.16791 Available: <https://onlinelibrary.wiley.com/doi/10.1111/apa.16791>
- 14 Baker KE, Wilson LM, Sharma R, et al. Hormone therapy, mental health, and quality of life among transgender people: a systematic review. *J Endocr Soc* 2021;5:bvab011.
  - 15 Chew D, Anderson J, Williams K, et al. Hormonal treatment in young people with gender Dysphoria: a systematic review. *Pediatrics* 2018;141:e20173742.
  - 16 Thompson L, Sarovic D, Wilson P, et al. A PRISMA systematic review of adolescent gender Dysphoria literature: 3) treatment. *PLOS Glob Public Health* 2023;3:e0001478.
  - 17 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71.
  - 18 Fraser L, Hall R, Taylor J, et al. The epidemiology, management and outcomes of children with gender-related distress/gender Dysphoria: a systematic review. PROSPERO 2021 Crd42021289659. 2021. Available: [https://www.crd.york.ac.uk/prosperto/display\\_record.php?ID=CRD42021289659](https://www.crd.york.ac.uk/prosperto/display_record.php?ID=CRD42021289659)
  - 19 Wilson LM, Baker KE, Sharma R, et al. Effects of Antiandrogens on prolactin levels among transgender women on estrogen therapy: a systematic review. *Int J Transgend Health* 2020;21:391–402.
  - 20 Ramos GGF, Mengai ACS, Daltro CAT, et al. Systematic review: puberty suppression with GnRH analogues in adolescents with gender incongruity. *J Endocrinol Invest* 2021;44:1151–8.
  - 21 Veritas Health Innovation. *Covidence systematic review software*. Melbourne, Australia: Veritas Health Innovation, 2023.
  - 22 Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2021. Available: [https://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)
  - 23 Burke SM, van Heeswijk JO, Menks WM, et al. Postnatal effects of sex hormones on click-evoked Otoacoustic emissions: a study of adolescents with gender Dysphoria. *Arch Sex Behav* 2020;49:455–65.
  - 24 de Vries ALC, Steensma TD, Doreleijers TAH, et al. Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. *J Sex Med* 2011;8:2276–83.
  - 25 de Vries ALC, McGuire JK, Steensma TD, et al. Young adult psychological outcome after puberty suppression and gender reassignment. *Pediatrics* 2014;134:696–704.
  - 26 Delemarre-van de Waal HA, Cohen-Kettenis PT. Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. *Eur J Endocrinol* 2006;155:S131–7.
  - 27 Klaver M, de Mutsert R, Wiepjes CM, et al. Early hormonal treatment affects body composition and body shape in young transgender adolescents. *J Sex Med* 2018;15:251–60.
  - 28 Klaver M, de Mutsert R, van der Loos MATC, et al. Hormonal treatment and cardiovascular risk profile in transgender adolescents. *Pediatrics* 2020;145:e20190741.
  - 29 Klink D, Caris M, Heijboer A, et al. Bone mass in young adulthood following Gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender Dysphoria. *J Clin Endocrinol Metab* 2015;100:E270–5.
  - 30 Schagen SEE, Cohen-Kettenis PT, Delemarre-van de Waal HA, et al. Efficacy and safety of Gonadotropin-releasing hormone agonist treatment to suppress puberty in gender Dysphoric adolescents. *J Sex Med* 2016;13:1125–32.
  - 31 Schagen SEE, Lustenhouwer P, Cohen-Kettenis PT, et al. Changes in adrenal androgens during puberty suppression and gender-affirming hormone treatment in adolescents with gender Dysphoria. *J Sex Med* 2018;15:1357–63.
  - 32 Schagen SEE, Wouters FM, Cohen-Kettenis PT, et al. Bone development in transgender adolescents treated with GnRH analogues and subsequent gender-affirming hormones. *J Clin Endocrinol Metab* 2020;105:e4252–63.
  - 33 Staphorsius AS, Kreukels BPC, Cohen-Kettenis PT, et al. Puberty suppression and executive functioning: an fMRI-study in adolescents with gender Dysphoria. *Psychoneuroendocrinology* 2015;56:190–9.
  - 34 Stoffers IE, de Vries MC, Hannema SE. Physical changes, laboratory parameters, and bone mineral density during testosterone treatment in adolescents with gender Dysphoria. *J Sex Med* 2019;16:1459–68.
  - 35 van de Griff TC, van Gelder ZJ, Mullender MG, et al. Timing of puberty suppression and surgical options for transgender youth. *Pediatrics* 2020;146:e20193653.
  - 36 van der Loos MA, Hellinga I, Vlot MC, et al. Development of hip bone geometry during gender-affirming hormone therapy in transgender adolescents resembles that of the experienced gender when pubertal suspension is started in early puberty. *J Bone Miner Res* 2021;36:931–41.
  - 37 van der Miesen AIR, Steensma TD, de Vries ALC, et al. Psychological functioning in transgender adolescents before and after gender-affirmative care compared with Cisgender general population peers. *J Adolesc Health* 2020;66:699–704.
  - 38 Vlot MC, Klink DT, den Heijer M, et al. Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in Transgender adolescents. *Bone* 2017;95:11–9.
  - 39 de Nie I, Mulder CL, Meibner A, et al. Histological study on the influence of puberty suppression and hormonal treatment on developing germ cells in Transgender women. *Hum Reprod* 2022;37:297–308.
  - 40 Achille C, Taggart T, Eaton NR, et al. Longitudinal impact of gender-affirming endocrine intervention on the mental health and well-being of Transgender youths: preliminary results. *Int J Pediatr Endocrinol* 2020;2020:8.
  - 41 Akgul S, Bonny AE, Ford N, et al. Experiences of gender minority youth with the Intrauterine system. *J Adolesc Health* 2019;65:32–8.
  - 42 Grimstad FW, Knoll MM, Jacobson JD. Oxandrolone use in Trans-masculine youth appears to increase adult height: preliminary evidence. *LGBT Health* 2021;8:300–6.
  - 43 Kuper LE, Stewart S, Preston S, et al. Body dissatisfaction and mental health outcomes of youth on gender-affirming hormone therapy. *Pediatrics* 2020;145:e20193006.
  - 44 Lynch MM, Khandheria MM, Meyer WJ. Retrospective study of the management of childhood and adolescent gender identity disorder using Medroxyprogesterone acetate. *Int J Transgenderism* 2015;16:201–8.
  - 45 Mejia-Otero JD, White P, Lopez X. Effectiveness of puberty suppression with Gonadotropin-releasing hormone agonists in Transgender youth. *Transgend Health* 2021;6:31–5.
  - 46 Neyman A, Fuqua JS, Eugster EA. Bicalutamide as an androgen blocker with secondary effect of promoting Feminization in male-to-female Transgender adolescents. *J Adolesc Health* 2019;64:544–6.
  - 47 Nokoff NJ, Scarbro SL, Moreau KL, et al. Body composition and markers of Cardiometabolic health in Transgender youth on Gonadotropin-releasing hormone agonists. *Transgend Health* 2021;6:111–9.
  - 48 Olson-Kennedy J, Streeter LH, Garofalo R, et al. Histrelin implants for suppression of puberty in youth with gender Dysphoria: A comparison of 50 Mcg/day (Vantas) and 65 Mcg/day (Supprelinia). *Transgend Health* 2021;6:36–42.
  - 49 Pine-Twaddell E, Newfield RS, Marinkovic M. Extended use of Histrelin implant in pediatric patients. *Transgend Health* 2023;8:264–72.
  - 50 Schulmeister C, Millington K, Kaufman M, et al. Growth in Transgender/gender-diverse youth in the first year of treatment with Gonadotropin-releasing hormone agonists. *J Adolesc Health* 2022;70:108–13.
  - 51 Strang JF, Chen D, Nelson E, et al. Transgender youth executive functioning: relationships with anxiety symptoms, autism spectrum disorder, and gender-affirming medical treatment status. *Child Psychiatry Hum Dev* 2022;53:1252–65.
  - 52 Tordoff DM, Wanta JW, Collin A, et al. Mental health outcomes in Transgender and Nonbinary youths receiving gender-affirming care. *JAMA Netw Open* 2022;5:e220978.
  - 53 Turban JL, King D, Carswell JM, et al. Pubertal suppression for Transgender youth and risk of suicidal Ideation. *Pediatrics* 2020;145:e20191725.
  - 54 Hisle-Gorman E, Schvey NA, Adirim TA, et al. Mental Healthcare utilization of Transgender youth before and after affirming treatment. *J Sex Med* 2021;18:1444–54.
  - 55 Carmichael P, Butler G, Masic U, et al. Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender Dysphoria in the UK. *PLoS One* 2021;16:e0243894.
  - 56 Costa R, Dunsford M, Skagerberg E, et al. Psychological support, puberty suppression, and Psychosocial functioning in adolescents with gender Dysphoria. *J Sex Med* 2015;12:2206–14.
  - 57 Ghelani R, Lim C, Brain C, et al. Sudden sex hormone withdrawal and the effects on body composition in late pubertal adolescents with gender Dysphoria. *J Pediatr Endocrinol Metab* 2020;33:107–12.
  - 58 Joseph T, Ting J, Butler G. The effect of GnRH analogue treatment on bone mineral density in young adolescents with gender Dysphoria: findings from a large national cohort. *J Pediatr Endocrinol Metab* 2019;32:1077–81.
  - 59 Russell I, Pearson B, Masic U. A longitudinal study of features associated with autism spectrum in clinic referred, gender diverse adolescents Accessing puberty suppression treatment. *J Autism Dev Disord* 2021;51:2068–76.
  - 60 Arcelus J, Claes L, Witcomb GL, et al. Risk factors for non-suicidal self-injury among Trans youth. *J Sex Med* 2016;13:402–12.
  - 61 Chiniara LN, Bonifacio HJ, Palmert MR. Characteristics of adolescents referred to a gender clinic: are youth seen now different from those in initial reports? *Horm Res Paediatr* 2018;89:434–41.
  - 62 Khatchadourian K, Amed S, Metzger DL. Clinical management of youth with gender Dysphoria in Vancouver. *J Pediatr* 2014;164:906–11.
  - 63 Navabi B, Tang K, Khatchadourian K, et al. Pubertal suppression, bone mass, and body composition in youth with gender Dysphoria. *Pediatrics* 2021;148:e2020039339.
  - 64 Waldner RC, Doulla M, Atallah J, et al. Leuprolide acetate and QTc interval in gender-diverse youth. *Transgend Health* 2023;8:84–8.
  - 65 Tack LJW, Craen M, Dhondt K, et al. Consecutive Lynestrenol and cross-sex hormone treatment in biological female adolescents with gender Dysphoria: a retrospective analysis. *Biol Sex Differ* 2016;7:14.
  - 66 Tack LJW, Craen M, Lapauw B, et al. Proandrogenic and Antiandrogenic Progestins in Transgender youth: differential effects on body composition and bone metabolism. *J Clin Endocrinol Metab* 2018;103:2147–56.
  - 67 Tack LJW, Heyse R, Craen M, et al. Consecutive cyproterone acetate and estradiol treatment in late-pubertal Transgender female adolescents. *J Sex Med* 2017;14:747–57.
  - 68 Perl L, Elkon-Tamir E, Segev-Becker A, et al. Blood pressure Dynamics after pubertal suppression with Gonadotropin-releasing hormone analogs followed by estradiol treatment in Transgender female adolescents: a pilot study. *J Pediatr Endocrinol Metab* 2021;34:741–5.

- 69 Perl L, Segev-Becker A, Israeli G, *et al*. Blood pressure Dynamics after pubertal suppression with Gonadotropin-releasing hormone analogs followed by testosterone treatment in Transgender male adolescents: A pilot study. *LGBT Health* 2020;7:340–4.
- 70 Segev-Becker A, Israeli G, Elkon-Tamir E, *et al*. Children and adolescents with gender Dysphoria in Israel: increasing referral and fertility preservation rates. *Endocr Pract* 2020;26:423–8.
- 71 Fontanari AMV, Vilanova F, Schneider MA, *et al*. Gender affirmation is associated with Transgender and gender Nonbinary youth mental health improvement. *LGBT Health* 2020;7:237–47.
- 72 Becker-Hebly I, Fahrenkrug S, Campion F, *et al*. Psychosocial health in adolescents and young adults with gender Dysphoria before and after gender-affirming medical interventions: a descriptive study from the Hamburg gender identity service. *Eur Child Adolesc Psychiatry* 2021;30:1755–67.
- 73 Luo X, Liang Y, Hou L, *et al*. Long-term efficacy and safety of Gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: A systematic review and meta-analysis. *Clin Endocrinol (Oxf)* 2021;94:786–96.
- 74 van der Loos MATC, Klink DT, Hannema SE, *et al*. Children and adolescents in the Amsterdam cohort of gender Dysphoria: trends in Diagnostic- and treatment Trajectories during the first 20 years of the Dutch protocol. *J Sex Med* 2023;20:398–409.
- 75 Masic U, Butler G, Carruthers P, *et al*. Trajectories of Transgender adolescents referred for endocrine intervention in England. *Arch Dis Child* 2022;107:1012–7.
- 76 van der Loos MATC, Hannema SE, Klink DT, *et al*. Continuation of gender-affirming hormones in Transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands. *Lancet Child Adolesc Health* 2022;6:869–75.
- 77 Chen D, Strang JF, Kolbuck VD, *et al*. Consensus parameter: research Methodologies to evaluate neurodevelopmental effects of pubertal suppression in Transgender youth. *Transgend Health* 2020;5:246–57.
- 78 NHS England. URN 1927 literature surveillance report. 2023. Available: [https://www.engage.nhs.uk/consultation/puberty-suppressing-hormones/user\\_uploads/literature-surveillance-report-on-gnrh-analogues-for-children-and-adolescents-with-gender-dysphoria-may-2023.pdf](https://www.engage.nhs.uk/consultation/puberty-suppressing-hormones/user_uploads/literature-surveillance-report-on-gnrh-analogues-for-children-and-adolescents-with-gender-dysphoria-may-2023.pdf)
- 79 Boogers LS, Reijtenbagh SJP, Wiepjes CM, *et al*. Time course of body composition changes in Transgender adolescents during puberty suppression and sex hormone treatment. *J Clin Endocrinol Metab* 2023;21:21.
- 80 Boogers LS, Wiepjes CM, Klink DT, *et al*. Transgender girls grow tall: adult height is unaffected by GnRh analogue and estradiol treatment. *J Clin Endocrinol Metab* 2022;107:e3805–15.
- 81 Willemsen LA, Boogers LS, Wiepjes CM, *et al*. Just as tall on testosterone; a neutral to positive effect on adult height of GnRh and testosterone in Trans boys. *J Clin Endocrinol Metab* 2023;108:414–21.
- 82 Ciancia S, Klink D, Craen M, *et al*. Early puberty suppression and gender-affirming hormones do not alter final height in Transgender adolescents. *Eur J Endocrinol* 2023;189:396–401.
- 83 van der Loos MATC, Vlot MC, Klink DT, *et al*. Bone mineral density in Transgender adolescents treated with puberty suppression and subsequent gender-affirming hormones. *JAMA Pediatr* 2023;177:1332.
- 84 Valentine A, Davis S, Furniss A, *et al*. Multicenter analysis of Cardiometabolic-related diagnoses in Transgender and gender-diverse youth: A Pedsnet study. *J Clin Endocrinol Metab* 2022;107:e4004–14.
- 85 McGregor K, McKenna JL, Williams CR, *et al*. Association of pubertal blockade at Tanner 2/3 with Psychosocial benefits in Transgender and gender diverse youth at hormone readiness assessment. *J Adolesc Health* 2023;12:S1054-139X(23)00560-8.
- 86 van Heesewijk J, Steenwijk MD, Kreukels BPC, *et al*. Alterations in the inferior Frontal-occipital Fasciculus - a specific neural correlate of gender Incongruence? *Psychol Med* 2023;53:3461–70.